HanaVax

10:30 AM - 10:45 AM (JST), Wednesday, March 6, 2019 ・ 2nd Floor
HanaVax is developing vaccines administered by small painless sprays into the nose. Our formulations retain the antigens on respiratory mucosal surfaces long time and initiate antigen-specific immune responses via the mucosal immune system. This results in more effective uptake, processing and presentation of the antigens by immune cells (e.g., nasal dendritic cells), which in turn results in strong antigen-specific T cell and B cell immune responses at both mucosal surfaces and in the systemic circulation for the protective immunity. This vaccination method has been shown to induce protective immunity against pneumococcal pneumonia in nonhuman primates.
Develop nasal vaccine against infectious diseases is our company business focus. Pneumococcal vaccine is our lead product. Our pipelines include HPV therapeutic vaccine, HSV vaccine, Non-typeable Haemophilus influenzae (NTHi) vaccine, RSV vaccine and TB vaccine.
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
pneumococcal nasal vaccine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2